Eli Lilly built up $1.5 billion in pre-launch inventory for its experimental oral weight-loss drug orforglipron, according to a regulatory filing.

In today’s Pharmaceutical Executive Daily, Eli Lilly builds a $1.5 billion stockpile of Orforglipron ahead of an FDA decision, PTC Therapeutics withdraws and plans to resubmit its Translarna NDA, and ...

Eli Lilly reinforced its push into next-generation immunology and oncology innovation through two major transactions: the ...

Kim Boericke, CEO, Veristat, discusses how Veristat is adapting clinical trials by using data, AI, and operational planning to optimize site selection, manage complex cell and gene therapy logistics, ...

Yerem Yeghiazarians founder, CEO of Soley Therapeutics, talks about how drug discovery is a team effort, noting that success ...

To be successful in the pharmaceutical industry, leaders must be willing to take risks. During his conversation with Pharmaceutical Executive, Leonard Mazur kept coming back to this point. According ...

PTC Therapeutics withdrew its New Drug Application (NDA) resubmission for Translarna (ataluren) in nonsense mutation Duchenne muscular dystrophy (nmDMD) following feedback from FDA indicating that the ...

Pharm Exec’s 21st Annual Pipeline Report examines emerging drug development classes, treatment modalities, and expansion pursuits in five therapeutic settings ripe for next-gen innovation.

Yerem Yeghiazarians founder, CEO of Soley Therapeutics, discusses how Soley uses human cells to guide drug discovery, ...

Pharm Exec’s 21st Annual Pipeline Report examines emerging drug development classes, treatment modalities, and expansion pursuits in five therapeutic settings ripe for next-gen innovation.

The EY deals leader discusses recent findings and trends from 2025.

In a conversation with Pharmaceutical Executive, Phesi founder and CEO Gen Li discusses his company’s recent global analysis of clinical trials. While the report once again showed that breast cancer ...